Miraparkin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole stimulates dopamine D2 and D3 receptors in the brain, mimicking the action of dopamine. This activation enhances dopaminergic signaling, which compensates for the reduced dopamine activity seen in Parkinson's disease and modulates sensory pathways involved in restless legs syndrome.

The dosage of Miraparkin is individualized. A qualified prescriber determines the appropriate starting dose, titration schedule, and maintenance dose based on the patient’s condition, age, renal function, and response to therapy. No fixed regimen is provided here.

Safety data for pramipexole in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Miraparkin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and necessary import documentation.

Miraparkin (pramipexole) is a non‑levodopa dopamine agonist, offering an oral option that can be used as monotherapy in early disease or as an adjunct to levodopa in later stages. Compared with other dopamine agonists such as ropinirole, pramipexole has a longer half‑life, allowing once‑daily dosing in many formulations, but individual response and side‑effect profiles vary.

Miraparkin should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Miraparkin is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistent timing with respect to meals helps maintain stable drug levels. Patients should follow the prescriber’s instructions regarding dose adjustments and timing.

Serious risks include impulse‑control disorders (such as compulsive gambling or shopping), hallucinations, sudden onset of sleep, severe depression or suicidal thoughts, and orthostatic hypotension that may cause fainting. Patients should be monitored closely for these events, and any concerning symptoms should be reported to a healthcare professional immediately.

Miraparkin is contraindicated in individuals with known hypersensitivity to pramipexole or any of its excipients. It should be used with caution, or avoided, in patients with severe renal impairment, uncontrolled psychiatric illness, or a history of impulse‑control disorders. A prescriber must evaluate each patient’s medical history before initiating therapy.